Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
BRAF+
•
Langerhans Cell Histiocytosis
Do you recommend using cell-free BRAFV600E to track response to therapy in pediatric patients with langerhans cell histiocytosis?
Related Questions
What is your standard for monitoring triglyceride level during therapy for ALL, particularly in regards to receiving pegaspargase?
If a pediatric patient has a prior history of cancer-associated thrombosis while receiving active treatment, can they be on estrogen-containing OCPs in the future?
What is your preferred treatment for refractory warm autoimmune hemolytic anemia with autoimmune neutropenia?
What workup needs to be performed on pediatric patients with warm autoimmune hemolytic anemia prior to initiation of treatment with immunosuppressants?
In pediatric patients with Hodgkin lymphoma who have a partial response after chemotherapy and multiple disease sites above and below the diaphragm, how do you approach radiotherapy planning considering cumulative dose and toxicity?
How do you choose between the different available CAR-T cell therapy products for the treatment of relapsed Ph-negative ALL?
For which pediatric oncology patients do you start bacterial prophylaxis, inpatient or outpatient, and what is your antibiotic of choice?
How do you counsel patients with acute intermittent porphyria when it comes to fasting for religious reasons?
In pure red cell aplasia, does peripheral blood-positive IgG for parvovirus have significance if persistently positive on retesting, but IgM and PCR are negative?
How do you approach adjuvant therapy for resected Stage I Ewing sarcoma of the kidney, and what chemotherapy regimen and cycle duration do you recommend?
